UK Life Sciences Company Directory

Non-viral intracellular delivery platform based on biomolecular condensates

PartitionBio is a biotechnology company developing a non-viral intracellular delivery platform based on liquid-liquid phase separation and biomolecular condensates. Its lead product, BubbleFect, is a room-temperature-stable, non-lipid reagent designed for bench-top use without specialist equipment or cold-chain…

Next-generation programmable gene insertion platform technology

Gene Weaver is a preclinical-stage biotechnology company developing a programmable, RNA-based gene insertion platform. Its RNA-guided enzymatic system functions as a complete molecular machine, locating the target site and inserting large DNA payloads to enable kilobase-scale gene insertion at virtually any genomic…

Near-infrared bioluminescence reagents for preclinical imaging research

Bioflares is a biotechnology company developing and supplying infraluciferin-based reagents and engineered luciferase enzymes for near-infrared bioluminescence imaging. Its patented infraluciferin substrate enables simultaneous dual-parameter imaging of two biological processes in living animals, supporting…

Surface acoustic wave nebuliser platform for inhaled drug delivery

Nebu~Flow is a UK medical technology company developing next-generation nebuliser devices using patented surface acoustic wave technology to aerosolise drugs into precisely controlled droplet sizes for deep lung deposition. The platform is designed to enable inhalation delivery of biologics, RNA-based formulations,…

Oral muscle-sparing small molecule therapies for obesity

Hawkhill Therapeutics is a pre-clinical biotechnology company developing oral, muscle-sparing therapeutics for obesity and metabolic health. Its programme targets a clinically validated mechanism to achieve fat-selective weight loss while preserving muscle mass, addressing a recognised limitation of current GLP-1…

Immune cell separation and expansion platform for cell therapies

CoED Biosciences is a biotech developing the Column of Expansion and Differentiation (CoED) platform, a consumable device integrating immune cell separation, functionalisation, and expansion in a single workflow. The system exploits the natural migratory behaviour of immune cells across membranes, replacing…

Computational DNA design for durable genetic medicines

Houdini Bio is an early-stage biotechnology company using computational synthetic biology to redesign DNA for improved performance in genetic medicines. The company is developing approaches to enhance the durability and scalability of gene expression, with potential applications across gene therapies and DNA-based…

E3 ligase inhibitors stabilising tumour suppressor proteins

Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant proteins. Its proprietary platform has been used to profile over 45 E3 ligases across oncology, cardiovascular, neurological, and autoimmune…

Cancer genetics testing and contract research

Oncologica provides molecular cancer diagnostics and contract research services from its laboratory at Chesterford Research Park near Cambridge. Its Oncofocus testing uses tumour DNA profiling to help clinicians identify potentially relevant targeted treatments and immunotherapies. The company also develops…

Synthetic platform for precision delivery of biologics in tissue repair

Renovos Biologics is a biotech company developing precision delivery technologies for regenerative medicine, drawing on decades of academic research in skeletal stem cells, biomaterials and translational orthopaedic science at the University of Southampton. Its proprietary synthetic platform enables injectable,…

Cell-free DNA capture reagents for liquid biopsy and cancer diagnostics

BIOCAPTIVA is a biotechnology company developing novel cell-free DNA capture technology to improve liquid biopsy for cancer research and diagnostics. Its proprietary polymer platform captures cfDNA directly from whole blood without centrifuges or additional reagents, delivering substantially higher cfDNA yields than…

Nanoparticle platform for targeted genetic medicine delivery

ViaNautis is a nanomedicine company developing a polymer nanoparticle platform for the targeted intracellular delivery of genetic therapeutic payloads across difficult-to-penetrate biological barriers. The platform is designed to encapsulate a broad range of genetic cargoes and guide them to specific tissues and cell…

Cell profiling and precision additives for biologic manufacturing

Silvia Bio is a University of Sheffield spin-out developing cell-profiling services and media additives for mammalian-cell biomanufacturing. Its platform identifies cellular bottlenecks limiting productivity and biologic product quality, then formulates bioreactor-compatible additives to address them without genetic…

Graphene nanocomposites and biomaterials for regenerative medicine research

NanoRegMed is a London biotechnology company developing graphene-based polymers and nanocomposites for regenerative medicine and industrial applications. Its Hastalex and BioHastalex materials have tunable properties for potential tissue repair and implant applications. The company also supplies reduced and…

CASPAROV AI platform for targets in heterogeneous cancers

Enedra Therapeutics develops targeted cancer medicines designed to address genetic diversity within solid tumours, a major cause of treatment resistance. Its CASPAROV platform combines cancer genomics, AI and functional biology to identify survival mechanisms shared across heterogeneous tumour cells. These convergent…

Engineered bacteriophages for precision antimicrobial discovery

BioPhoundry is an engineering biology company developing bacteriophage-based technologies for precision antimicrobial research. Its Phax platform combines machine learning, synthetic biology and cell-free production to accelerate phage discovery and engineering. The company aims to generate tailored phages for…

RNAi therapeutics for Parkinson's and neurodegenerative diseases

Valaya Bio is developing RNA interference (RNAi) therapeutics for age-related neurodegenerative diseases, initially Parkinson's disease. Its platform uses precision oligonucleotides designed to modulate upstream molecular regulators implicated in multiple disease pathways, including mitochondrial dysfunction,…

Blood-based liquid biopsy for endothelial glycocalyx and microvascular health

Dimension Biotechnologies is a biotech developing a rapid, blood-based diagnostic for microvascular health based on analysis of the endothelial glycocalyx, the molecular layer lining blood vessel walls whose biochemical integrity is disrupted early in cardiovascular disease, kidney disease, diabetes, and sepsis. The…

Gut microbiome tests predicting biologic drug response in IBD

AlphaBiomics is a precision medicine company developing diagnostics that analyse the gut microbiome to guide treatment decisions. Its lead test uses a stool sample collected at home and machine learning analysis of microbial sequencing data to predict which patients with inflammatory bowel disease are likely to…

Engineered bacterial nanosyringes for intracellular protein delivery

NanoSyrinx is a discovery-stage biotechnology company developing a platform for targeted intracellular delivery of protein and peptide therapeutics. Based on naturally occurring bacterial nanomachines, the company's technology is engineered to deliver biological payloads directly to the cytosol of targeted cells…